Claritev Corp

Claritev Corp(CTEV)股票分析

$23.000

+0.357 (+1.55%)收盤時

Loading chart…
最高
23.833
開盤
23.550
成交量加權均價
23.04
成交量
237.50K
市值
—
最低
22.285
成交金額
5.47M
企業價值/稅息折舊攤銷前利潤(TTM)
8.56

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.

AI 分析 of Claritev Corp (CTEV)

買進

Claritev Corporation (CTEV) appears to be a good buy right now. The current price is $23.50, which is significantly lower than the average analyst price target of $40, indicating a potential upside of over 70%. Additionally, the company has shown a positive trend with a 6.24% increase over the past five days and a narrowed quarterly loss of $59.23 million, down from $62.64 million year-over-year, reflecting improved operational efficiency. However, a key risk is the high debt-to-equity ratio, which stands at 0%, indicating potential financial instability if market conditions worsen.

估值指標

Claritev Corp(CTEV)目前預期本益比為 2.94,5 年平均預期本益比為 -0.61。

預期本益比

合理
5 年均值 P/E
-0.61
目前P/E
2.94
高估
3.48
低估
-4.70

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
9.23
目前EV/EBITDA
8.56
高估
9.87
低估
8.58

預期股價營收比

合理
5 年均值 P/S
0.57
目前P/S
0.36
高估
0.84
低估
0.31

Alphio AI 對 CTEV 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%CTEV

$27.94

情境價格

基

基準

基準 · 50%CTEV

$26.34

情境價格

悲

悲觀

悲觀 · 25%CTEV

$21.83

情境價格

持有 CTEV 的大戶

A

Ares Management LLC

+ 持有CTEV

-13.44%

3個月報酬率

事件時間軸

2026-09-22 (ET)

09:30:00

Claritev Selected to Support World Trade Center Health Program

2026-09-15 (ET)

09:30:00

Claritev Appoints Ben Letham as Director

2026-08-07 (ET)

05:30:00

Company Raises FY26 Adjusted EBITDA Outlook to $620M

05:30:00

Claritev Q2 Revenue Reaches $257.48M, Exceeds Expectations

2026-07-14 (ET)

13:30:00

Justice Department Expands Antitrust Investigation into Claritev

資訊

CTEV 常見問題 —— 由 Alphio AI 解答

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors. It operates in the Industrials sector.

Claritev Corporation (CTEV) appears to be a good buy right now. The current price is $23.50, which is significantly lower than the average analyst price target of $40, indicating a potential upside of over 70%. Additionally, the company has shown a positive trend with a 6.24% increase over the past five days and a narrowed quarterly loss of $59.23 million, down from $62.64 million year-over-year, reflecting improved operational efficiency. However, a key risk is the high debt-to-equity ratio, which stands at 0%, indicating potential financial instability if market conditions worsen.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易